Turning Point Therapeutics, an early stage biotech developing tyrosine kinase inhibitors for treating cancer, raised $167 million by offering 9.3 million shares at $18, the high end of the range of $16 to $18.
Turning Point Therapeutics plans to list on the Nasdaq under the symbol TPTX. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as lead managers on the deal.
Turning Point Therapeutics prices IPO at $18, the high end of the range
April 17, 2019

